Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease

References

• Global Initiative for Chronic Obstructive Lung Disease [webpage on the Internet]Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease [updated Jan 2014] Available from: http://www.goldcopd.com/guidelines-global-strategy-for-diagnosis-management.htmlAccessed November 12, 2014
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease [webpage on the Internet]Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease [updated 2014] Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report2014_Feb07.pdfAccessed December 12, 2014
   Google Scholar
• KarnerCChongJPoolePTiotropium versus placebo for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20147CD00928525046211
   PubMed Web of Science ®Google Scholar
• TashkinDPCelliBSennSA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med2008359151543155418836213
   PubMed Web of Science ®Google Scholar
• SinghSLokeYKFurbergCDInhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysisJAMA2008300121439145018812535
   PubMed Web of Science ®Google Scholar
• SinghSLokeYKEnrightPLFurbergCDMortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trialsBMJ2011342d321521672999
   PubMed Web of Science ®Google Scholar
• JaraMWentworthC3rdLanesSA new user cohort study comparing the safety of long-acting inhaled bronchodilators in COPDBMJ Open201223e000841
   Web of Science ®Google Scholar
• ShortPMWilliamsonPAElderDHLipworthSISchembriSLipworthBJThe impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting beta-agonist therapy in COPDChest20121411818621799028
   PubMed Web of Science ®Google Scholar
• DongYHLinHHShauWYWuYCChangCHLaiMSComparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trialsThorax2013681485623042705
   PubMed Web of Science ®Google Scholar
• VerhammeKMAfonsoARomioSStrickerBCBrusselleGSturkenboomMUse of tiotropium Respimat® SMI vs tiotropium Handihaler® and mortality in patients with COPDEur Respir J201342360661523520322
   PubMed Web of Science ®Google Scholar
• WiseRAAnzuetoACottonDTIOSPIR InvestigatorsTiotropium Respimat inhaler and the risk of death in COPDN Engl J Med2013369161491150123992515
   PubMed Web of Science ®Google Scholar
• UlrikCSOnce-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefitInt J Chron Obstruct Pulmon Dis2012767367823055716
   PubMed Web of Science ®Google Scholar
• SechaudRRenardDZhang-AubersonLde la MotteSDrollmannAKaiserGPharmacokinetics of multiple inhaled NVA237 doses in patients with chronic obstructive pulmonary disease (COPD)Int J Clin Pharmacol Ther201250211812822257577
   PubMed Web of Science ®Google Scholar
• FogartyCHattersleyHDi ScalaLDrollmannABronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patientsRespir Med2011105333734221144724
   PubMed Web of Science ®Google Scholar
• VerkindreCFukuchiYFlémaleASustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patientsRespir Med2010104101482148920541381
   PubMed Web of Science ®Google Scholar
• VogelmeierCVerkindreCCheungDSafety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patientsPulm Pharmacol Ther201023543844420416390
   PubMed Web of Science ®Google Scholar
• D’UrzoAFergusonGTvan NoordJAEfficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trialRespir Res20111215622151296
   PubMed Web of Science ®Google Scholar
• KerwinEHébertJGallagherNEfficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 studyEur Respir J20124051106111423060624
   PubMed Web of Science ®Google Scholar
• BeehKMSinghDDi ScalaLDrollmannAOnce-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trialInt J Chron Obstruct Pulmon Dis2012750351322973092
   PubMed Web of Science ®Google Scholar
• European Medicines Agency [webpage on the Internet]Eklira^® Genuair^® (aclidinium bromide)London, UKEuropean Medicines Agency2014 [updated Dec, 2014]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002211/human_med_001571.jsp&mid=WC0b01ac058001d124Accessed December 1, 2014
   Google Scholar
• US Food and Drug Administration [webpage on the Internet]Tudorza^® Pressair^® (aclidinium bromide)Rockville, MDUS Food and Drug Administration2012 [updated 2012]. Available from: http://www.access-data.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Drug-DetailsAccessed December 1, 2014
   Google Scholar
• GavaldàAMiralpeixMRamosICharacterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profileJ Pharmacol Exp Ther2009331274075119710368
   PubMed Web of Science ®Google Scholar
• GavaldàAViñalsMAubetsJGrasJEffect of formoterol alone and in combination with aclidinium on electrocardiograms in dogsEur Respir J201240Suppl 56P2116
   Google Scholar
• JansatJMLamarcaRde MiquelGSchrödterAMiletzkiBGurniakMSafety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participantsJ Clin Pharmacol200949101239124619592595
   PubMed Web of Science ®Google Scholar
• LasseterKCDilzerSJansatJMGarcia GilECaractaCOrtizSSafety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteersPulm Pharmacol Ther20122519319922366196
   PubMed Web of Science ®Google Scholar
• LasseterKCAubetsJChuecosFGarcia GilEAclidinium bromide, a long-acting antimuscarinic, does not affect QT interval in healthy subjectsJ Clin Pharmacol201051692393220959525
   PubMed Web of Science ®Google Scholar
• SchmidKPascualSGarcia GilEOrtizSJansatJMPharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: A phase I, open-label, single-dose clinical trialClin Ther201032101798181221194604
   PubMed Web of Science ®Google Scholar
• de la MotteSBeierJSchmidKPascualSJansatJMGarcia GilEPharmacokinetics and safety of aclidinium bromide in younger and elderly patients with chronic obstructive pulmonary diseaseInt J Clin Pharmacol Ther201250640341222541745
   PubMed Web of Science ®Google Scholar
• FuhrRMagnussenHSaremKEfficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPDChest2012141374575221903737
   PubMed Web of Science ®Google Scholar
• SinghDMagnussenHKirstenAA randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patientsPulm Pharmacol Ther201225324825322497752
   PubMed Web of Science ®Google Scholar
• KerwinEMD’UrzoADGelbAFACCORD I study investigators. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I)COPD2012929010122320148
   PubMedGoogle Scholar
• JonesPWSinghDBatemanEDEfficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN studyEur Respir J201240483083622441743
   PubMed Web of Science ®Google Scholar
• RennardSIScanlonPDFergusonGTACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patientsClin Drug Investig201313312893904
   Google Scholar
• GelbAFTashkinDPMakeBJZhongXGarcia GilECaractaCLAS-MD-35 study investigatorsLong-term safety and efficacy of twice-daily aclidinium bromide in patients with COPDRespir Med2013107121957196523916502
   PubMed Web of Science ®Google Scholar
• D’UrzoAKerwinERennardSHeTGarcia GilECaractaCOne-year extension study of ACCORD COPD I: safety and efficacy of two doses of twice-daily aclidinium bromide in patients with COPDCOPD201310450051023679347
   PubMedGoogle Scholar
• BeierJKirstenAMMrózREfficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb studyCOPD201310451152223819698
   PubMedGoogle Scholar
• ChanezPBurgePSDahlRAclidinium bromide provides long-acting bronchodilation in patients with COPDPulm Pharmacol Ther2010231152119683590
   PubMed Web of Science ®Google Scholar
• JoosGFSchelfhoutVJPauwelsRABronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patientsRespir Med2010104686587220044242
   PubMed Web of Science ®Google Scholar
• JonesPWRennardSIAgustiAEfficacy and safety of once-daily aclidinium in chronic obstructive pulmonary diseaseRespir Res2011125521518460
   PubMed Web of Science ®Google Scholar
• NiHSoeZMoeSAclidinium bromide for stable chronic obstructive pulmonary diseaseCochrane Database Syst Rev20149CD01050925234126
   PubMed Web of Science ®Google Scholar
• DonohueJFMinimal clinically important differences in COPD lung functionCOPD20052111112417136971
   PubMedGoogle Scholar
• AgustiAJonesPWBatemanEDImprovement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: results from ATTAINEur Respir J201138Suppl 55874
   Google Scholar
• MahlerDAWitekTJJrThe MCID of the transition dyspnea index is a total score of one unitCOPD2005219910317136969
   PubMedGoogle Scholar
• JonesPWQuirkFHBaveystockCMThe St George’s Respiratory QuestionnaireRespir Med199185Suppl B25311759018
   PubMed Web of Science ®Google Scholar
• KerwinEJonesPD’UrzoARekedaLGarcia GilECaractaCTwice-daily aclidinium bromide in COPD patients: a pooled analysis of lung function in the ACCORD-COPD I and ATTAIN trialsEur Respir J201240Suppl 56P2892
   Google Scholar
• JonesPWSinghDKerwinELamarcaRCaractaCGarcia GilEReduced COPD exacerbations associated with aclidinium bromide versus placebo: a pooled analysis of Phase III dataThorax201267Suppl 2A146
   Web of Science ®Google Scholar
• LeidyNKWilcoxTKJonesPWRobertsLPowersJHSethiSEXACT-PRO Study GroupStandardizing measurement of chronic obstructive pulmonary disease exacerbations: reliability and validity of a patient-reported diaryAm J Respir Crit Care Med2011183332332920813886
   PubMed Web of Science ®Google Scholar
• FuhrRMagnussenHSinghDde MiquelGCaractaCGarcia GilEPatient assessments of ease of use of Genuair® versus Aerolizer® and HandiHaler®Eur Respir J201138Suppl 55P3979
   Google Scholar
• van der PalenJGinkoTKrokerAPreference, satisfaction and errors with two dry powder inhalers in patients with COPDExpert Opin Drug Deliv20131081023103123745954
   PubMed Web of Science ®Google Scholar
• DonohueJRennardSCelliBRekedaLGarcia GilECaractaCSafety and tolerability of aclidinium bromide in patients with COPD: pooled results from long-term phase III studiesChest20121424688A
   Google Scholar
• European Medicines Agency Committee for Medicinal Products for Human Use (CHMP)Eklira Genuair: CHMP assessment report5242012 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002211/WC500132663.pdfAccessed February 25, 2015
   Google Scholar
• Food and Drug AdministrationTudorza Pressair: Summary review of regulatory action7202012 http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202450Orig1s000SumR.pdfAccessed February 25, 2015
   Google Scholar
• MelaniASBonaviaMCilentiVInhaler mishandling remains common in real life and is associated with reduced disease controlRespir Med2011105693093821367593
   PubMed Web of Science ®Google Scholar